To assess the value of CCR2+CD4+ T cells and MCP-1 levels in the longitudinal course, three consecutive therapeutical BALs were analyzed in three patients with PAP (P17, P18, P19) and one patient with cholesterol pneumonitis (P22). This evidence concerns the gene CD4 and pulmonary alveolar proteinosis.